Silexion Therapeutics Corp Ordinary Shares (SLXN)
Stock · NASDAQ · Health Care
$0.153as of 10/16/2026
Price chart
Active signals
SLXN Signal Track Record
How signals performed across all stocks →What SLXN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakout | 22 | +0.3% | 59% | September 18, 2026 |
| Bollinger Band Breakdown | 16 | -14.5% | 25% | September 24, 2026 |
| Volume Spike | 10 | -25.7% | 10% | September 28, 2026 |
| Any 20-session window (baseline) | 0.0% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SLXN
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of panc…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 13
- Website
- www.moringaac.com/
Fundamentals
- 1-day range
- $0.2599$0.299
- Market cap
- $1.90M
- P/E (trailing)
- —
- P/E (forward)
- -0.41
- EPS (trailing)
- $-56.45
- Dividend yield
- —
- Beta
- -0.33
- Avg. volume
- 9.82M
Forecasts
1 analyst ratings
Silexion Therapeutics Corp Ordinary Shares Competitors
Chosen by industry and closest market cap.
- SLXNSilexion Therapeutics Corp Ordinary Shares$0.153▼ 19.05%Market cap $1.90MP/E —$0.2362$42.6
- SCNIScinai Immunotherapeutics Ltd. American Depositary Shares$0.752▼ 16.63%Market cap $1.30MP/E 0.16$0.75$15.65
- BTTCBlack Titan Corporation Ordinary Shares$0.368▼ 6.84%Market cap $1.02MP/E —$0.3415$10.05
- TVGNWTevogen Inc. Warrant$0.0689▼ 1.57%Market cap $320.8KP/E —$0.0253$0.08
- SLXNWSilexion Therapeutics Corp Warrant$0.0054▼ 10.00%Market cap $21.3KP/E —$0.0051$0.1508
- BKHABlack Hawk Acquisition Corporation Class A Ordinary Shares$6.01▼ 12.26%Market cap $—P/E 136.64$9.5$23
- CLDICalidi Biotherapeutics Inc. Common Stock$0.837▼ 3.79%Market cap $4.38MP/E —$0.82$27.84
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SLXN Silexion Therapeutics Corp Ordinary Shares | $1.90M | — | $0.153 | ▼ 19.05% | $0.2362$42.6 |
| SCNI Scinai Immunotherapeutics Ltd. American Depositary Shares | $1.30M | 0.16 | $0.752 | ▼ 16.63% | $0.75$15.65 |
| BTTC Black Titan Corporation Ordinary Shares | $1.02M | — | $0.368 | ▼ 6.84% | $0.3415$10.05 |
| TVGNW Tevogen Inc. Warrant | $320.8K | — | $0.0689 | ▼ 1.57% | $0.0253$0.08 |
| SLXNW Silexion Therapeutics Corp Warrant | $21.3K | — | $0.0054 | ▼ 10.00% | $0.0051$0.1508 |
| BKHA Black Hawk Acquisition Corporation Class A Ordinary Shares | $— | 136.64 | $6.01 | ▼ 12.26% | $9.5$23 |
| CLDI Calidi Biotherapeutics Inc. Common Stock | $4.38M | — | $0.837 | ▼ 3.79% | $0.82$27.84 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Which stocks are gapping on Wednesday?ChartMill · 9/30/2026
- Wednesday's pre-market session: top gainers and losersChartMill · 9/30/2026
- Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic CancerYahoo · 9/30/2026
- 12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga · 9/30/2026
- Silexion Therapeutics Announces First Patient Dosed Phase 2/3 Clinical Trial Evaluating Lead Candidate, SIL204, In Patients With Locally Advanced Pancreatic CancerBenzinga · 9/30/2026
- Why FingerMotion Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving PremarketBenzinga · 9/30/2026
- Top movers analysis one hour before the close of the markets on 2026-09-29: top gainers and losers in today's session.ChartMill · 9/29/2026
- Most active stocks in Tuesday's sessionChartMill · 9/29/2026
Insider Activity
Insider Actions →- Shirvan Mitchell · June 4, 2026 · Grant6.0K
- Hadar Ilan · June 4, 2026 · Grant10.0K
- Horenshtein Hadar Mirit · June 4, 2026 · Grant7.5K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
Silexion Reports First Patient Dosed in Phase 2/3 SIL204 Trial
Silexion Therapeutics announced that the first patient has been successfully dosed in its Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer. The milestone indicates progress toward evaluating the drug’s safety and efficacy in a larger patient group. The announcement may influence investor interest as the company moves closer to potential regulatory submissions. The trial’s results will be key to assessing SIL204’s future development path.
Silexion Reports First Patient Dosed in Phase 2/3 SIL204 Trial. Silexion Therapeutics announced that the first patient has been successfully dosed in its Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer. The milestone indicates progress toward evaluating the drug’s safety and efficacy in a larger patient group. The announcement may influence investor interest as the company moves closer to potential regulatory submissions. The trial’s results will be key to assessing SIL204’s future development path.